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both administered every 21 days. Clinic visits were estimated
from grade four toxicities not requiring hospitalisation. Using
the perspective of the national health care system, Spanish costs
were applied to RU data from patients who received treatment
(N = 541). Unit costs were obtained from published sources.
Mean cost per patient was calculated. RESULTS: Baseline char-
acteristics were well-balanced (72% male, 88% performance
status 0/1, 75% Stage IV). Patients received a median of four
cycles in both treatment arms. Survival was similar between arms
(HR = 0.99), with a median of about eight months. Grade 3/4
neutropenia and neutropenic fever occurred more frequently
with docetaxel (40% vs. 5%, 13% vs. 2%, respectively; p <
0.001). Most other grade 3/4 toxicities occurred at low rates
(£5%) and were similar between arms. Patients receiving doc-
etaxel were hospitalised more frequently and received more gran-
ulocyte colony-stimulating factors, erythropoietin, antibiotics
and antifungals. Patients receiving docetaxel were more likely to
incur extra clinic visits to manage grade four toxicity. Patients
treated with pemetrexed received more transfusions. Total mean
cost per patient was 309€ for pemetrexed and 1036€ for doc-
etaxel. Hospitalisation and outpatient medications accounted for
majority of costs (67% and 25% in the pemetrexed group,
respectively, and 77% and 21% in the docetaxel group, respec-
tively). CONCLUSIONS: Pemetrexed demonstrated similar efﬁ-
cacy to docetaxel in second-line treatment of NSCLC, but with
a superior toxicity proﬁle. The differences in toxicity are
expected to translate to considerable cost savings to the Spanish
health care system.
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OBJECTIVES: Health-related quality of life assessments are
increasingly used in clinical decision-making. A phase III trial of
pemetrexed versus docetaxel in second-line therapy for advanced
non-small cell lung cancer (NSCLC) showed similar efﬁcacy;
however, key safety beneﬁts were reported with pemetrexed. Fol-
lowing a pilot study in the UK (UK), an expanded study in the
UK and France was conducted to determine patient value asso-
ciated with individual toxicity proﬁles. METHODS: A discrete
choice conjoint analysis was used to quantify patient preference
and willingness-to-pay for chemotherapy. A review of trial data,
along with expert opinion, identiﬁed clinically meaningful toxi-
cities that were statistically signiﬁcantly different. Levels of risk
of: febrile neutropenia (requiring hospitalisation) and nausea,
neuropathy, arthralgia/myalgia, alopecia (all grades), were eval-
uated in the pilot. Following the pilot, arthralgia/myalgia was
removed and a sample size of 70 pre-treated NSCLC patients per
country was calculated. Patients considered unique, randomly
generated sets of 10 pair-wise choice scenarios representing levels
for toxicity attributes plus cost, designed to elicit trade-offs.
Logistic regression analysis was applied to the stated scenario
preferences against the individual attribute levels. RESULTS: In
the expanded study, patients (N = 140) were predominantly
male, mean age 61 years, and 60% Stage III, which is compara-
ble to the pilot. Pemetrexed would be accepted in preference to
docetaxel at zero cost, with a probability of 0.81 in the UK and
0.90 in France. The probability of choosing pemetrexed over
docetaxel decreases with increasing cost; however, patient pref-
erence remains strong at 0.70 in the UK and 0.85 in France with
a cost per cycle of £400 and 2500€, respectively. CONCLU-
SIONS: NSCLC patients showed clear preference for the
enhanced toxicity proﬁle with pemetrexed, which translates to
valuable quality of life gains in the second-line setting. These
data provide sensitive strength of preference measures. Addi-
tional country studies are planned.
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OBJECTIVES: To identify and describe currently available
instruments to measure patient-reported outcomes and percep-
tions of cancer-related fatigue. METHODS: A literature review
was performed in several electronic sources including the U.S.
National Cancer Institute website and the Medline database
(1966–2004) using the keywords: fatigue, asthenia, question-
naire, scale, instrument, oncology, cancer, assessment, measure,
measurement, expectation/s, relief, satisfaction, perception/s,
worry/ies. Articles located were hand-searched for further rele-
vant articles. A citation was selected for review when it referred
to the use or development of patient reported instrument(s) to
measure the impact of cancer-related fatigue or its treatment
and/or patients expectations, beliefs and concerns regarding
cancer-related fatigue. For each questionnaire located the fol-
lowing data was reviewed: instruments’ name, target population,
item number, dimensions, response scale and time frame.
RESULTS: In total, 35 citations were selected and reviewed,
which referred to 30 different instruments (27 patient-reported
outcome questionnaires –PRO’s– and 3 epidemiological survey
instruments) used to measure several aspects of cancer-related
fatigue. Questionnaires ranged from a single item to 40 items,
and the number of dimensions from 1 to 7. Almost all of the
PRO’s focused on aspects such as the intensity, frequency and
duration of fatigue, though some also measured one or more of
the following: quality of life, distress, psychological impact and
impact on motivation/activity, and barriers to patient-physician
communication. The survey instruments located were more
likely to focus on patient’s attitudes and beliefs regarding 
physician-patient interaction, psychosocial issues, accessing
information, satisfaction with fatigue management and percep-
tions of causes, among others. CONCLUSIONS: Though there
appears to be a surfeit of instruments to measure the intensity,
frequency and duration of cancer-related fatigue, and some
emphasis on the way fatigue affects quality of life there are few
instruments which incorporate other aspects such as beliefs,
expectations and attitudes which may also be useful in clinical
practice.
PCN33
HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA
Lloyd A1, Kimberley S1, Cornes P2,Tolley K3
1MEDTAP International, London, UK; 2Royal United Hospital Bath,
Bath, UK; 3ORTHO BIOTECH, Buckinghamshire, UK
OBJECTIVES: To determine the preferences of the general public
for health state descriptions of anaemia associated with cancer
treatment. The majority of patients undergoing chemotherapy
develop anaemia which leads to fatigue, and decreased quality
of life (i.e. associated with a haemoglobin under 12g/dl). Treat-
ing cancer related fatigue has not been given the importance of
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other treatment related effects such as nausea. The present study
was designed to estimate the utility decrement associated with
increasing severities of anaemia. METHODS: Existing trial data
was summarized in order to deﬁne health states related to the
following haemoglobin levels: 7.0–8.0; 8.0–9.0; 9.0–10.0;
10.0–10.5; 10.5–11.0; 11.0–12.0; and 12+g/dL. These health
states were based on the FACT-An fatigue related items and were
reviewed by clinicians and two quality of life experts. Forty inter-
views with the general public (recruited through advertisements)
were conducted where participants were asked to rate the health
states using a visual analogue scale (VAS) and standard gamble
(SG). RESULTS: Mean (+95% CI) utility values were calculated
for each health state anchored against death. The VAS scores
ranged from 19.3 ± 3.9 for 7–8g/dL Hb to 53.8 3 ± 6.7 for 12+
g/dL Hb. The standard gamble derived utility values showed a
broadly linear change from 0.59 ± 0.10 for 7–8g/dL Hb to 0.75
± 0.09 for 12+g/dL Hb. CONCLUSIONS: The health state
utility scores show a linear decrement in line with worsening
anaemia. These data underline the importance of cancer related
fatigue for the general public.
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OBJECTIVES: Anaemia is a common complication in cancer
patients undergoing chemotherapy. Although quality-of-life
(QoL) in CRA has been studied, utility values related to anaemia
severity are lacking. The UK National Institute for Clinical
Excellence (NICE) requests cost-utility analysis based on quality-
adjusted life-years (QALY’s) incorporating utilities elicited using
public preferences. The objective was to use an appropriate
method to estimate the impact of CRA, from a societal perspec-
tive. METHODS: A time-trade-off (TTO) questionnaire was
designed and administered to a sample of laypeople: CRA health
states were deﬁned and described, based on the EuroQoL (EQ-
5D) instrument, and the Functional Assessment of Cancer
Therapy—Anaemia (FACT-An) instrument, and validated by
clinical experts and cancer patients who had experienced
anaemia. These descriptions were valued using the TTO elicita-
tion method. Written informed consent was obtained and trained
interviewers conducted surveys during February–March, 2004.
RESULTS: In total, 110 respondents were interviewed; ﬁnal
analyses were performed on 106 respondents’ data. Resultant
utility scores were converted to ratios, reﬂecting the baseline of
“cancer and chemotherapy, with no anaemia”. Mean utility
scores [SE] are 0.856 [0.014] for the no-anaemia state, and 0.781
[0.016], 0.615 [0.020] and 0.481 [0.020] for mild, moderate and
severe anaemia states, respectively (Ratios of 1.00, 0.91, 0.72,
and 0.56, respectively). CONCLUSIONS: This study strongly
highlights a societal view that severity of cancer-related anaemia
will signiﬁcantly affect patient utility. For example, a change
from no-anaemia to severe anaemia is predicted to approxi-
mately halve utility, independent of other factors. TTO 
appears to be a valid, and sufﬁciently sensitive method to high-
light this effect. The ratios of relative effect are applicable to a
range of “baseline” cancer utilities as multiplicative factors 
to estimate impact of anaemia within this broader context. 
These results could be incorporated within appraisals of thera-
pies for CRA, and satisfy certain health technology assessment
criteria.
PCN35
VALUATION OF SOCIETAL PREFERENCE BETWEEN
THERAPIES FOR CANCER-RELATED ANAEMIA (CRA):
RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS
BLOOD TRANSFUSION
Ossa DF1, McIntosh E2, Briggs A2, Cowell W3, Littlewood T4,
Sculpher M5
1Occam Outcomes, Oxford, UK; 2HERC—University of Oxford,
Oxford, UK; 3Health Care Management Group—Roche, Welwyn
Garden City, UK; 4John Radcliffe Hospital, Oxford, UK; 5University of
York,York, UK
OBJECTIVES: Blood transfusion and rh-EPO are alternative
treatment options for CRA. Potential beneﬁts of rh-EPO treat-
ment include improved health outcomes, but also more conve-
nient administration. The objective was to elicit public
preference scores associated with differences in these aspects of
treatment, and subsequently use these “valued preferences”
within a willingness-to-pay (WTP) analysis of cost-effectiveness
of NeoRecormon (rh-EPO beta) versus transfusion. METHODS:
A discrete choice experiment (DCE) was designed and adminis-
tered to a sample of laypeople. Important aspects of treatment
were deﬁned through a literature review, plus input from expert
clinician and patient interviews. An out-of-pocket cost attribute
was included in order to estimate WTP values. Lay people were
surveyed during February–March, 2004. A random effects probit
model was used to analyse the data. WTP values for aspects of
treatment were obtained by estimating the marginal rate of sub-
stitution between treatment attributes and the cost coefﬁcient.
Mean values of a unit improvement in each attribute level were
used in an economic welfare analysis of the value of shifting from
transfusion to NeoRecormon. RESULTS: A total of 110 respon-
dents completed the DCE questionnaire. Final analyses were per-
formed on 1086 observations, and showed high consistency,
reliability, and face-validity. The following preferences were sig-
niﬁcant predictors of choice (p < 0.001): Effectiveness: Higher
level of relief from fatigue; Administration of treatment: Lower
duration, subcutaneous/intravenous versus cannula injection,
and GP versus hospital location; Safety: Lower risk of infec-
tion/allergic reaction; and Lower cost. Attribute levels were
valued higher for NeoRecormon than for transfusion. This is
reﬂected in an incremental welfare value of GBP368[95% CI:
GBP318-GBP419]. CONCLUSIONS: This study shows that the
public value the favourable attributes of treatment with rh-EPO,
and indicates a likely patient preference for treatment with Neo-
Recormon over blood transfusion. This type of WTP analysis
could be used to aid decisions regarding optimal management of
CRA.
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OBJECTIVES: Anastrozole provides a treatment alternative for
patients with EBC who cannot tolerate tamoxifen or in whom
the drug is contraindicated. This study aimed to examine the
value patients place on the ability of a treatment to decrease the
